Skip to content

Psilocybin: all studies

Page 50 of 439: studies 491 to 500 of 4,389, newest first. Back to the psilocybin overview

Research

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy for patients with advanced cancer: protocol for a multi-method feasibility trial

Pilot and Feasibility Studies October 28, 2025 Candice Richardson, Cindy Chan, Emily Macgregor et al. 1 citation

BACKGROUND: Individuals with advanced cancer often experience high levels of distress for which there are few standardized treatment approaches. Our multidisciplinary team has combined existing evidence-based approaches into Psilocybin-assisted Existential, Attachment, and RelationaL (PEARL) therapy. PEARL therapy combines elements from psilocybin-assisted psychotherapy, including preparatory...

Psilocybin's effects on obsessive-compulsive behaviors: A systematic review of preclinical and clinical evidence

Psychedelics October 28, 2025 James J Gattuso, Bilgenur Bezcioglu, Carey Wilson et al. 1 citation

Psilocybin is a serotonergic psychedelic with growing evidence for efficacy in mood disorders, and its therapeutic potential in obsessive—compulsive disorder (OCD) and related conditions is increasingly recognised but remains understudied. We systematically evaluated clinical and preclinical evidence on psilocybin's effects on obsessive and compulsive behaviours with attention to translational...

Adverse event reporting and management in psilocybin therapy clinical trials: A systematic review to guide clinical and research protocol development

Progress in Neuro-Psychopharmacology and Biological Psychiatry October 23, 2025 Danielle Bukovsky, Aron Amaev, Jianmeng Song et al.

Psilocybin, a psychedelic prodrug, has gained renewed interest for its potential to treat various psychiatric disorders, including depression, anxiety, and substance use disorders. While promising, concerns remain regarding its safety profile and the management of potential adverse events (AEs). This systematic review aimed to evaluate the incidence, nature, and severity of adverse events and...

Novel Psilocin Derivatives as Serotonergic Psychedelic Agents for Treating CNS Disorders

ACS Medicinal Chemistry Letters October 22, 2025 Ram W. Sabnis

High Resolution Image Download MS PowerPoint Slide Provided herein are novel psilocin derivatives as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating central nervous system (CNS) disorders, and processes for preparing such compounds.

Is there more to magic mushrooms than psilocybin?

C&EN Global Enterprise October 20, 2025 Special To C En Mara Johnson-Groh

In a suburb of Vancouver, Canada, a nondescript three-story building sits alongside a strip of parking lots. From the outside, it looks like an ordinary commercial office space. But inside is something more extraordinary: rows of shelves stacked with plastic tubs full of magic mushrooms—mushrooms that contain the hallucinogenic chemical psilocybin. In a year, enough psychedelic mushrooms can be...

Cognitive and subjective effects of psilocybin microdosing: Results from two double-blind placebo-controlled longitudinal trials

Neuropharmacology October 17, 2025 Luisa Prochazkova, Josephine Marschall, Dominique P. Lippelt et al. 3 citations

ObjectiveMicrodosing psychedelics has been widely reported to enhance focus and problem-solving, sparking interest in its potential to treat attentional disorders such as ADHD. However, existing studies largely rely on anecdotal evidence and lack adequate placebo control.MethodsThis study contributes to the literature by examining the longitudinal effects of microdosing psilocybin truffles in...

DOI: 10.1016/j.neuropharm.2025.110722 (opens in new tab) Psilocybin Cognition Hallucinogen Cognitive assessment system +3

Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacity: A Scoping Review

Preprints.org October 17, 2025 Jacques Suspène, Sarah Huet, Sabine Berteina‐raboin et al. preprint

Alcohol use disorder is a psychiatric condition characterized by excessive alcohol consumption. The drugs that are used to treat it often fail to prevent relapse. At the same time, psilocybin is increasingly being investigated for the treatment of various substance use disorder. This review aims to evaluate the results of the most recent clinical trials assessing psilocybin as a treatment for...

Analysis of Serotonin in Caenorhabditis Elegans Subjected to Micro-Dosing with Psilocybin| Iris Publishers

Insights in Chemistry and Biochemistry October 15, 2025 Douglas B. Craig

method was developed for the analysis of serotonin in Caenorhabditis elegans. Samples were subjected to solvent-solvent extraction from basic conditions into n-heptanol. The serotonin was then back-extracted into acetic acid, the solution diluted into basic buffer, and labelled with 3-(2-furoyl) quinoline-2-carboxaldehyde in the presence of cyanide. The sample was analyzed by capillary...

DOI: 10.33552/icbc.2025.03.000562 (opens in new tab) Caenorhabditis elegans Iris biosensor Capillary electrophoresis Fluorescence +4

Psilocybin exerts differential effects on social behaviour and inflammation in mice in contexts of activity-based anorexia (ABA)

bioRxiv (Cold Spring Harbor Laboratory) October 15, 2025 Sheida Shadani, Erika Greaves, Zane B. Andrews et al. preprint

Abstract Psychedelics, particularly psilocybin, have shown therapeutic potential across several psychiatric conditions, including depression, anxiety, obsessive-compulsive disorder, and anorexia nervosa (AN). These disorders often share social deficits that may be effectively alleviated by psychedelics considering their use has been linked with emotional empathy and enhanced social cognition....

Psilocybin’s effect on human brain synaptic plasticity

Research Square October 10, 2025 Gitte M. Knudsen, Annette Johansen, Pontus Plavén-sigray et al. preprint

Abstract Psychedelics such as psilocybin have been linked to enhanced neuroplasticity and symptom relief in affective disorders, but the neurobiological mechanisms and impact of environmen-tal context remain unclear. Here, we tested whether a single dose of psilocybin alters synap-tic density in healthy individuals and whether setting-dependent subjective experience shapes this effect. Fifteen...